| Hepatitis C: The beginning of the endkey elements for successful European and national strategies to eliminate HCV in Europe |
20 |
| Mortality, liver transplantation and hepatic complications in patients with treatment-naive chronic hepatitis B treated with entecavir vs tenofovir |
20 |
| Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey |
17 |
| Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era |
17 |
| Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study |
17 |
| Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia |
17 |
| Hepatitis B virus and risk of non-Hodgkin lymphoma: An updated meta-analysis of 58 studies |
16 |
| Safety and efficacy of telbivudine in late pregnancy to prevent mother-to-child transmission of hepatitis B virus: A multicenter prospective cohort study |
14 |
| New treatment options for delta virus: Is a cure in sight? |
12 |
| High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme |
12 |
| Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study |
11 |
| Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir |
11 |
| Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine |
11 |
| Treatment adherence and support for people who inject drugs taking direct-acting antiviral therapy for hepatitis C infection |
11 |
| Distribution of ABO/Rh blood groups and their association with hepatitis B virus infection in 3.8 million Chinese adults: A population-based cross-sectional study |
10 |
| Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study |
10 |
| Treatment of HCV infection in Poland at the beginning of the interferon-free erathe EpiTer-2 study |
10 |
| Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis |
10 |
| The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease |
10 |
| Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected data |
9 |
| Eliminating hepatitis C: The importance of frequent testing of people who inject drugs in high-prevalence settings |
9 |
| Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection |
9 |
| Roadmap to functional cure of chronic hepatitis B: An expert consensus |
9 |
| Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: A comparative analysis |
9 |
| Natural history of serum HBV-RNA in chronic HBV infection |
9 |
| Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system |
9 |
| New viral biomarkers for Hepatitis B: Are we able to change practice? |
8 |
| Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy |
8 |
| Comparative evaluation of GPR versus APRI and FIB-4 in predicting different levels of liver fibrosis of chronic hepatitis B |
8 |
| HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues |
8 |
| Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison |
8 |
| The epidemiology of hepatitis B and hepatitis C infections in China from 2004 to 2014: An observational population-based study |
8 |
| Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4 |
8 |
| HBV seroprevalence after 25 years of universal mass vaccination and management of non-responders to the anti-Hepatitis B vaccine: An Italian study among medical students |
8 |
| Diabetes poses a higher risk of hepatocellular carcinoma and mortality in patients with chronic hepatitis B: A population-based cohort study |
8 |
| Increased oestradiol in hepatitis E virus-infected pregnant women promotes viral replication |
8 |
| Hepatitis E virus seroprevalence, seroincidence and seroreversion in the German adult population |
8 |
| Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA |
8 |
| The hepatitis C cascade of care in people who inject drugs in Dar es Salaam, Tanzania |
7 |
| Real-world impact of direct acting antiviral therapy on health-related quality of life in HIV/Hepatitis C co-infected individuals |
7 |
| Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment |
7 |
| Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience |
7 |
| Field evaluation of GeneXpert((R)) (Cepheid) HCV performance for RNA quantification in a genotype 1 and 6 predominant patient population in Cambodia |
7 |
| Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort |
7 |
| Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011 |
7 |
| Therapeutic vaccination for chronic hepatitis B: A systematic review and meta-analysis |
7 |
| Clinical features and determinants of chronicity in hepatitis E virus infection |
7 |
| Clinical effectiveness, cost effectiveness and acceptability of community-based treatment of hepatitis C virus infection: A mixed method systematic review |
7 |
| Use of HCV-infected organs in solid organ transplantation: An ethical challenge but plausible option |
7 |
| Assessing hepatitis C spontaneous clearance and understanding associated factorsA systematic review and meta-analysis |
7 |
